Next Biomedical

Next Biomedical (NEXTBIOMEDICAL) is a South Korean medical device company founded in 2014 and listed on KOSDAQ (389650). Headquartered in Incheon, South Korea, the company specializes in nano-based drug delivery systems and therapeutic materials for interventional medical procedures. Its core technology platform enables minimally invasive treatment across gastrointestinal, vascular, and orthopedic applications. Notable products include Nexpowder, a hemostatic powder agent designed for gastrointestinal bleeding. The company combines biomedical materials science with drug delivery innovation to develop next-generation medical devices for clinical use in interventional medicine.